{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3"},{"groupId":"OG001","value":"5.8"},{"groupId":"OG002","value":"6.9"}]}],"title":"Hemoglobin-Low: Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2"},{"groupId":"OG001","value":"5.5"},{"groupId":"OG002","value":"5.0"}]}],"title":"Neutrophils-Low: Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8"},{"groupId":"OG001","value":"1.9"},{"groupId":"OG002","value":"0.8"}]}],"title":"Neutrophils-Low: Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"12.7"},{"groupId":"OG002","value":"12.9"}]}],"title":"Platelets-Low: Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3"},{"groupId":"OG001","value":"2.8"},{"groupId":"OG002","value":"2.5"}]}],"title":"Platelets-Low: Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1"},{"groupId":"OG001","value":"3.9"},{"groupId":"OG002","value":"3.0"}]}],"title":"Alkaline Phosphate-High: Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4"},{"groupId":"OG001","value":"9.1"},{"groupId":"OG002","value":"8.0"}]}],"title":"Alanine Transaminase-High: Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.3"},{"groupId":"OG002","value":"0.6"}]}],"title":"Alanine Transaminase-High: Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1"},{"groupId":"OG001","value":"11.9"},{"groupId":"OG002","value":"6.9"}]}],"title":"Aspartate Aminotransferase-High: Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.3"},{"groupId":"OG002","value":"0.3"}]}],"title":"Aspartate Aminotransferase-High: Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"0.3"},{"groupId":"OG002","value":"1.1"}]}],"title":"Creatinine-High: Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.3"}]}],"title":"Creatinine-High: Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3"},{"groupId":"OG001","value":"4.7"},{"groupId":"OG002","value":"5.2"}]}],"title":"Potassium-Low: Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"1.7"},{"groupId":"OG002","value":"0.6"}]}],"title":"Potassium-Low: Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3"},{"groupId":"OG001","value":"0.3"},{"groupId":"OG002","value":"0.3"}]}],"title":"Total Bilirubin-High: Grade 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"361"},{"groupId":"OG002","value":"363"}],"units":"Participants"}],"description":"Laboratory results were graded according to NCI CTCAE version 4.0. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activity of daily living with inability to perform bathing, dressing and undressing, feeding self, using the toilet, taking medications but not bedridden. Grade 4: An immediate threat to life. Urgent medical intervention is required in order to maintain survival.","groups":[{"description":"Participants received trastuzumab plus either docetaxel or paclitaxel. The regimen was chosen at the investigator's discretion. Option 1: trastuzumab 8 mg/kg via IV infusion on Day 1 of Cycle 1, then 6 mg/kg IV on Day 1 of each subsequent 3-week cycle; plus a minimum of 6 cycles with docetaxel 75 or 100 mg/m\\^2 IV on Day 1 of each 3-week cycle. Option 2: trastuzumab 4 mg/kg IV on Day 1 of Cycle 1, then 2 mg/kg IV weekly beginning on Day 8 of Cycle 1; plus a minimum of 18 weeks with paclitaxel 80 mg/m\\^2 IV weekly. Treatment continued until disease progression, unacceptable toxicity, or study termination. If trastuzumab or docetaxel were discontinued for toxicity, the other agent could be continued as monotherapy.","id":"OG000","title":"Trastuzumab + Taxane"},{"description":"Participants received trastuzumab emtansine plus pertuzumab-placebo. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the placebo IV infusion, on Day 1 of each 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.","id":"OG001","title":"Trastuzumab Emtansine + Placebo"},{"description":"Participants received trastuzumab emtansine plus pertuzumab. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the pertuzumab IV infusion, on Day 1 of each 3-week cycle. Pertuzumab was given as 840 mg IV on Day 1 of Cycle 1, then 420 mg IV on Day 1 of each subsequent 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.","id":"OG002","title":"Trastuzumab Emtansine + Pertuzumab"}],"paramType":"NUMBER","populationDescription":"Safety population. Number of participants analyzed=participants with available data for the outcome.","reportingStatus":"POSTED","timeFrame":"Day 1, 8, and 15 of Cycle 1-3 and on Day 1 of each subsequent cycle up to 50 months from randomization until clinical cutoff of 16-Sept-2014","title":"Percentage of Participants With Grade 3-4 Laboratory Parameters","type":"SECONDARY","unitOfMeasure":"percentage of participants"}